6 research outputs found
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naĂŻve and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic option for patients with incurable DR mCRPC
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naĂŻve and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic o
Study of fractional diabetes model with and without complication class
This study investigates Diabetes Mellitus, focusing on global variations and complications for human health. We employ the ABC fractional derivative to develop a fractional-ordered diabetes model that incorporates complications for deeper understanding. This study is crucial for identifying patterns and trends by examining Diabetes Mellitus region-wise, aiding in targeted interventions and healthcare strategies, and using the ABC fractional derivative for a more accurate representation of the complexities associated with the disease, leading to more effective modeling and analysis. Our research yields important results that distinguish it from previous studies. Specifically, we investigate the stability and existence conditions of the proposed fractional-ordered diabetes model. Additionally, we employ the Adomian decomposition Laplace transform method to obtain solutions, enabling us to analyze the dynamics of the system comprehensively. Through graphical interpretations, we compare the recovery rates of diabetes in susceptible patients, both with and without complications. Regional analysis reveals varying prevalences and characteristics of Diabetes Mellitus, requiring tailored healthcare approaches. By incorporating complications into the fractional-ordered model, we enhance our understanding of the disease’s progression and its impact on recovery rates. These insights contribute to the broader field of diabetes research and offer valuable implications for clinical practice and public health policy
Fractional mathematical model of Listeria infection caused by pre-cooked package food
This article introduces a novel mathematical approach for modeling and analyzing Listeria infection dynamics by considering a system of fractional-order differential equations to understand the complexities. The homotopy perturbation general transform method (HPGTM) is applied to derive approximate solutions for the fractional-order Listeria infection model to obtain valuable insights. The obtained numerical and graphical solutions are rigorously analyzed to explore the effect of fractional orders on the dynamics of Listeria infections. Furthermore, we explore the existence, uniqueness, and stability properties of the solutions, unveiling the critical parameters influencing infection spread and persistence